Journey Medical Corp (DERM)
NASDAQ (CM) NASDAQ (CM) Primary 
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Q1 2026 Earnings Call Transcript
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
Journey Medical Corporation (DERM) Q4 2025 Earnings Call Transcript
Journey Medical Corporation (DERM) Q3 2025 Earnings Call Transcript
Journey Medical Corporation ( DERM ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President, CEO & Director Joseph Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Scott Henry - Alliance Global Partners, Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division Mayank Mamtani - B.
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Journey Medical Corporation (DERM) Q1 2025 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srinivas Sidgiddi - Vice President, Research and Development Ramsey Alloush - Chief Operating Officer and General Counsel Conference Call Participants Scott Henry - AGP Kalpit Patel - B. Riley Securities Thomas Flatten - Lake Street Capital Markets Operator Ladies and gentlemen, thank you for standing by.
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.53 per share a year ago.
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
Journey Medical (DERM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Journey Medical (DERM) Surges 9.1%: Is This an Indication of Further Gains?
Journey Medical (DERM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Journey Medical Corporation (DERM) Q4 2024 Earnings Call Transcript
Journey Medical Corporation (NASDAQ:DERM ) Q4 2024 Results Conference Call March 26, 2025 4:30 PM ET Company Participants Jaclyn Jaffe - Senior Director, Corporate Operations Claude Maraoui - Co-Founder, President and CEO Joseph Benesch - Chief Financial Officer Louis Donati - Director of Market Access Srini Sidgiddi - Vice President, Research and Development Ramsey Alloush - General Counsel and Corporate Secretary Conference Call Participants Thomas Flaten - Lake Street Capital Markets Scott Henry - AGP Brandon Folkes - Rodman & Renshaw Jason Wittes - Roth Capital Kalpit Patel - B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates
Journey Medical Corporation (DERM) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.12 per share a year ago.
Journey Medical Corporation: Emrosi's Launch Could Be A Turning Point
Journey Medical's future hinges on Emrosi™, a new formulation of minocycline for rosacea, showing superior efficacy over Oracea® in Phase III trials. Despite current financial challenges and a need for additional funding, Emrosi's market exclusivity until 2039 and strong trial results offer significant potential. Dermatologists' acceptance and PBM positioning are crucial for Emrosi's success, given its proven efficacy and potential to replace Oracea.
Journey Medical Corporation (DERM) Reports Q3 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.80 per share a year ago.
